The mid-stage success is encouraging, but taking on Takeda won’t be easy.

Biocon and Zentiva have celebrated the “first generic liraglutide approved in a major regulated/ICH market” after an endorsement from the UK’s MHRA.

UK liquids specialist Rosemont Pharmaceuticals has appointed a new chief corporate development officer to drive M&A. Meanwhile, EuroAPI has named a chief transformation officer, Zentiva’s CEO has joined Medicines for Europe’s executive committee, Hikma has changed company secretary, and Xbrane has made alterations to its nominations committee.

After China, India sees the arrival of a biosimilar to Novo Nordisk’s Victoza at a sharp discount, while action also appears to be heating up for the Danish firm's high-flying GLP-1, semaglutide, in both markets.